Louise Anna Andrea Gerbens

Louise Anna Andrea Gerbens

Auto-generated profile, based on publicly available information

Louise Anna Andrea Gerbens

Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PSP.I. Spuls
P.I. Spuls
LGL.A.A. Gerbens
L.A.A. Gerbens
ESE. Simpson
E. Simpson
CAC.J. Apfelbacher
C.J. Apfelbacher
JCJ.R. Chalmers
J.R. Chalmers
TCThe Home Initiative Collaborators
The Home Initiative Collaborators

30 May 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
LWL.E.M. Wijs
L.E.M. Wijs
ABA.L. Bosma
A.L. Bosma
NENicole Erler
Nicole Erler
LHL.M. Hollestein
L.M. Hollestein
LGL.A.A. Gerbens
L.A.A. Gerbens
DHD.J. Hijnen
D.J. Hijnen
Background Dupilumab is the first biologic registered for the treatment of moderate‐to‐severe atopic dermatitis (AD), and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, there are limited daily practice data available for dupilumab, especially when it is combined with systemic immunosuppressants. Objectives To evaluate dupilumab treatment in daily practice in patients with AD. Methods In this observational cohort study, we prospectively included all adult patients with AD who had been treated with dupilumab in two university hospitals in the Netherlands. Concomitant systemic immunosuppressive treatment was monitored. Physician‐reported outcome measures and patient‐reported outcome measures (PROMs) after ≥ 12 weeks of follow‐up were analysed. We used a linear mixed‐effects model to determine changes in scores during follow‐up. Results Ninety‐five patients were included. Of these, 62 patients were using systemic immunosuppressants at baseline; the use of systemic immunosuppressants was continued during dupilumab treatment in 43 patients. From baseline to 16 weeks of treatment, the estimated mean Eczema Area and Severity Index score (0–72) decreased from 18·6 [95% confidence interval (CI) 16·0–21·4)] to 7·3 (95% CI 5·4–10·0), and the estimated mean PROMs showed a decrease of 41–66%. Investigator's Global Assessment 0 or 1 (clear/almost clear) was reached in 38% of the patients. Five patients discontinued dupilumab treatment due to side‐effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex virus (HSV) reactivation were reported in 62% and 8% of the patients, respectively. Conclusions Dupilumab treatment in daily practice shows a clinically relevant improvement of physician‐reported outcome measures and PROMs, which is in line with efficacy data from clinical trials. Besides frequently reported eye symptoms and orofacial (nonocular) HSV reactivation, there were no apparent safety concerns.

13 July 2016 in Allergy
Verified
Journal Article
Closed access
PDF file
LGLouise A.A. Gerbens
Louise A.A. Gerbens
CPCecilia A.C. Prinsen
Cecilia A.C. Prinsen
JCJoanne R. Chalmers
Joanne R. Chalmers
ADAaron M. Drucker
Aaron M. Drucker
LKLaura B. von Kobyletzki
Laura B. von Kobyletzki
TIThe Harmonising Outcome Measures For Eczema (Home) Initiative
The Harmonising Outcome Measures For Eczema (Home) Initiative

10 April 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
LGL.A.A. Gerbens
L.A.A. Gerbens
SHS.A.S Hamann
S.A.S Hamann
MBM.W.D. Brouwer
M.W.D. Brouwer
ERE. Roekevisch
E. Roekevisch
MLM.M.G. Leeflang
M.M.G. Leeflang
PSP.I. Spuls
P.I. Spuls

18 February 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
FVF.M. Vermeulen
F.M. Vermeulen
LGL.A.A. Gerbens
L.A.A. Gerbens
JSJ. Schmitt
J. Schmitt
MDM. Deleuran
M. Deleuran
Alan IrvineAlan Irvine
Alan Irvine
TTthe international TREAT Registry Taskforce
the international TREAT Registry Taskforce
Background For many years dermatologists have had access to few therapies for patients with moderate‐to‐severe atopic eczema (AE). New promising therapies are entering the market but conventional phototherapies and systemic therapies have more well‐known safety‐profiles, lower costs and wider availability. Objectives To provide insight into current prescribing practices of conventional photo‐ and systemic immunomodulatory therapies for adults with chronic AE and the factors influencing these prescribing practices before biologics and other novel therapeutics become routine clinical practice. Methods In this exploratory study dermatologists were invited to participate in an online survey via a mailing list of the European Academy of Dermatology and Venereology and national societies. Data were collected on participant characteristics (including clinical practices data), the use of phototherapies and systemic therapies and factors influencing their use. Results From 30 European countries, 238 out of 361 dermatologists willing to participate (65.9%) completed the survey. For phototherapy (prescribed by 84.7%), most preferred narrow‐band ultraviolet‐B as first line (80.9%) and psoralen and ultraviolet‐A as second (21.6%). For systemic therapy (prescribed by 95.2%) ciclosporin (54.1%), oral corticosteroids (32.6%) and methotrexate (30.7%) were used first line. Dermatologists mostly relied on personal experience for prescribing phototherapy and systemic therapy. Azathioprine and mycophenolate acid were prescribed by only 135 (59%) and 85 (37.1%) participants in total, mostly due to a lack of personal experience. Conclusions This study provides insight into prescribing practices for conventional photo‐ and systemic therapies in Europe and shows that off‐label therapies are also preferred as first line choice of systemic therapy.

4 February 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
FVF.M. Vermeulen
F.M. Vermeulen
LGL.A.A. Gerbens
L.A.A. Gerbens
ABA.L. Bosma
A.L. Bosma
CAC.J. Apfelbacher
C.J. Apfelbacher
Alan IrvineAlan Irvine
Alan Irvine
TTthe International TREAT Registry Taskforce
the International TREAT Registry Taskforce
Background Comparative, real‐life and long‐term evidence on the effectiveness and safety of photo‐ and systemic therapy in moderate‐to‐severe atopic eczema (AE) is limited. Such data must come from well‐designed prospective patient registries. Standardisation of data collection is needed for direct comparisons and data pooling. Objectives To reach consensus on how and when to measure the previously defined domain items of the TREatment of Atopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult AE patients. Methods Proposals for the measurement instruments were based on the recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, expert opinions and systematic reviews of the literature. The proposals were discussed at multiple face‐to‐face consensus meetings, one teleconference and via email. The frequency of follow‐up visits was determined by an expert survey. Results A total of 16 experts from 7 countries participated in the ‘how to measure’ consensus process and 12 external experts were consulted. Consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow‐up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined. Conclusions This core dataset for national AE research registries will aid the comparability and pooling of data across centres and country borders and enable international collaboration to assess the long‐term effectiveness and safety of photo‐ and systemic therapy used in patients with AE.